Verified ComparisonLast updated: 31 March 2026
Tesofensine vs Semaglutide
Tesofensine (triple monoamine reuptake inhibitor) increases CNS norepinephrine/dopamine/serotonin. Semaglutide is an approved GLP-1 agonist. Different mechanisms for metabolic research.
Tesofensine
Metabolic
3.8/ 5
B+
Semaglutide
Metabolic
4.3/ 5
A−
Editor's note
Semaglutide is approved; Tesofensine shows higher weight loss in trials but faces safety concerns.
| Criterion | Tesofensine | Semaglutide |
|---|---|---|
| Mechanism | Monoamine reuptake inhibition | GLP-1 receptor agonism |
| Weight loss in trials | Very high (15-20%) | Substantial (15-22%) |
| Appetite suppression pathway | Central (CNS) | Peripheral (GI/systemic) |
| Regulatory approval | Not approved (development halted) | Approved (many countries, AU) |
| Safety profile | Cardiovascular concerns | Established |
Frequently asked questions
Phase III trials showed cardiovascular safety signals, leading development programs to pause.
Want to read the full reviews?